Clinical trial · Observational
A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma
FRILLY: A Retrospective Single-centre Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Tumour lysis syndrome (TLS) occurs as a consequence of the rapid destruction of malignant cells, spontaneously and/or in response to cytotoxic agents and immunotherapies. TLS is a feature of highly proliferative diseases with heavy tumor burden, such as high-grade non-Hodgkin lymphomas (NHL, typically Burkitt's lymphoma). We evaluated fractionating first rituximab dose to prevent TLS in a real-life B-cell NHL cohort of patients treated at University Hospital of Geneva between 2010 and 2020.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aggressive B-Cell Non-Hodgkin Lymphoma | Aggressive B-Cell Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fractionated first dose rituximab | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of clinical lysis syndrome (CTLS) in patients receiving fractionated Rituximab infusion for high-grade B-cell lymphoma.
- timeFrame
- 10 days (day -2 and day + 7 after first rituximab infusion)
- description
- To evaluate the incidence of clinical tumor lysis syndrome (CTLS) in patients receiving fractionated Rituximab infusion for high-grade B-cell lymphoma.
Secondary outcomes (1)
- measure
- Incidence of biochemical lysis syndrome (LTLS) in patients receiving fractionated Rituximab infusion for high-grade B-cell lymphoma.
- timeFrame
- 10 days (day -2 and day + 7 after first rituximab infusion)
- description
- To evaluate the incidence of biochemical tumor lysis syndrome (LTLS) in patients receiving fractionated Rituximab infusion for high-grade B-cell lymphoma.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed or relapsing histologically proven high-grade B-cell lymphoma patients treated with fractionated Rituximab infusion, considered as ≥ 2 consecutive infusions, at least 24 hours apart Exclusion Criteria: * Unproven histologically high-grade B-cell lymphoma * Patients who receive a single day Rituximab infusion * Patients under long-term dialysis before Rituximab started * Age ≤ 18 years * Absence of written informed consent
References
Publications (1)
- DERIVEDMohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, Stenner F, Tamburini J, Lang N. Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice. Cancer Rep (Hoboken). 2024 Oct;7(10):e1983. doi: 10.1002/cnr2.1983. PMID 39410860